{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:23Z","timestamp":1791464243666,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/ijgc-2023-005065","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T13:26:00Z","timestamp":1711632360000},"page":"879-885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5694-5439","authenticated-orcid":false,"given":"Soyoun Rachel","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashna","family":"Parbhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Q","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Hogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-2969","authenticated-orcid":false,"given":"Taymaa","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-005065_bb0010","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/jnci\/djz106","article-title":"Annual report to the nation on the status of cancer, featuring cancer in men and women age 20-49 years","volume":"111","author":"Ward","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2023-005065_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1136\/ijgc-2023-005065_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0511-7","article-title":"Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer","volume":"12","author":"Kim","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-005065_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030416","article-title":"Tailoring ovarian cancer treatment: implications of BRCA1\/2 mutations","volume":"11","author":"Madariaga","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-005065_bb0030","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2023-005065_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/bcr3332","article-title":"Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence","volume":"14","author":"Turner","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1136\/ijgc-2023-005065_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PAS.0000000000000556","article-title":"Invasion patterns of metastatic extrauterine high-grade serous carcinoma with BRCA germline mutation and correlation with clinical outcomes","volume":"40","author":"Hussein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-005065_bb0045","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/modpathol.2013.237","article-title":"Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency","volume":"27","author":"Reyes","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2023-005065_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2004.12.047","article-title":"Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel","volume":"97","author":"Kommoss","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005065_bb0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-005065_bb0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.canlet.2015.08.028","article-title":"High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation","volume":"369","author":"Gorodnova","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1136\/ijgc-2023-005065_bb0065","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ygyno.2021.07.010","article-title":"The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma","volume":"162","author":"Kim","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005065_bb0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/1878-0261.12817","article-title":"Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program","volume":"15","author":"Care","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1136\/ijgc-2023-005065_bb0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2022.06.026","article-title":"Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer","volume":"166","author":"Piedimonte","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005065_bb0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-005065_bb0085","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005065_bb0090","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/medicina58111611","article-title":"Survival and chemosensitivity in advanced high grade serous epithelial ovarian cancer patients with and without a BRCA germline mutation: more evidence for shifting the paradigm towards complete surgical cytoreduction","volume":"58","author":"De Jong","year":"2022","journal-title":"Medicina"},{"key":"10.1136\/ijgc-2023-005065_bb0095","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/ijgc-2018-000175","article-title":"BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy","volume":"29","author":"Gorodnova","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005065_bb0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2015.07.101","article-title":"Outcome of neoadjuvant chemotherapy in BRCA1\/2 mutation positive women with advanced-stage mullerian cancer","volume":"139","author":"Mahdi","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005065_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-6688-8","article-title":"Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer","volume":"20","author":"Lee","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-005065_bb0110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ijgc-2021-003116","article-title":"BRCA status and platinum sensitivity in advanced ovarian cancer according to chemotherapy response score","volume":"32","author":"Ergasti","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005065_bb0115","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.21276","article-title":"Prognostic impact of BRCA1 pathogenic and BRCA1\/BRCA2 unclassified variant mutations in patients with ovarian carcinoma","volume":"104","author":"Majdak","year":"2005","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-005065_bb0120","first-page":"235","article-title":"Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1","volume":"4","author":"Aida","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-005065_bb0125","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-005065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:30:09Z","timestamp":1753234209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24014087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1048891X24014087"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-005065","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-005065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}